Tumor-targeting and microenvironment-responsive smart nanoparticles for combination therapy of antiangiogenesis and apoptosis

ACS Nano

Volumn 7, Issue 3, 2013, Pages 2860-2871

  Huang, Shixian ^a   Shao, Kun ^a   Liu, Yang ^a   Kuang, Yuyang ^a   Li, Jianfeng ^a   An, Sai ^a   Guo, Yubo ^a   Ma, Haojun ^a   Jiang, Chen ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

cell penetrating peptide; chemotherapy; combination therapy; tumor microenvironment; tumor targeting nanoparticles; VEGF

Indexed keywords

CELL-PENETRATING PEPTIDE; COMBINATION THERAPY; TUMOR MICROENVIRONMENT; TUMOR-TARGETING; VEGF;

BLOOD VESSELS; CELL DEATH; CHEMOTHERAPY; DRUG DELIVERY; ENZYME ACTIVITY; ENZYME INHIBITION; NANOPARTICLES; PEPTIDES; RNA;

TUMORS;

ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CELL PENETRATING PEPTIDE; DOXORUBICIN; DRUG CARRIER; GELATINASE A; MMP2 PROTEIN, HUMAN; NANOPARTICLE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ACTIVE TRANSPORT; ANIMAL; APOPTOSIS; ARTICLE; CHEMISTRY; DRUG ANTAGONISM; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG SCREENING; HUMAN; MALE; METABOLISM; MOUSE; NANOTECHNOLOGY; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PHYSIOLOGY; TUMOR CELL LINE; TUMOR MICROENVIRONMENT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL TRANSPORT, ACTIVE; CELL LINE, TUMOR; CELL-PENETRATING PEPTIDES; DOXORUBICIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; HUMANS; MALE; MATRIX METALLOPROTEINASE 2; MICE; MICE, NUDE; NANOPARTICLES; NANOTECHNOLOGY; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84875648834     PISSN: 19360851     EISSN: 1936086X     Source Type: Journal    
DOI: 10.1021/nn400548g     Document Type: Article

References (50)

1. Chambers, A. F.; Groom, A. C.; MacDonald, I. C. Dissemination and Growth of Cancer Cells in Metastatic Sites Nat. Rev. Cancer 2002, 2, 563-572
2. Folkman, J. What Is the Evidence That Tumors Are Angiogenesis Dependent J. Natl. Cancer Inst. 1990, 82, 4-6
3. McMahon, G. VEGF Receptor Signaling in Tumor Angiogenesis Oncologist 2000, 5, 3-10
4. Jain, R. K.; di Tomaso, E.; Duda, D. G.; Loeffler, J. S.; Sorensen, A. G.; Batchelor, T. T. Angiogenesis in Brain Tumours Nat. Rev. Neurosci. 2007, 8, 610-622
5. Ohta, Y.; Endo, Y.; Tanaka, M.; Shimizu, J.; Oda, M.; Hayashi, Y.; Watanabe, Y.; Sasaki, T. Significance of Vascular Endothelial Growth Factor Messenger RNA Expression in Primary Lung Cancer Clin. Cancer Res. 1996, 2, 1411-1416
6. Liu, T.; Ye, L.; He, Y.; Chen, X.; Peng, J.; Zhang, X.; Yi, H.; Peng, F.; Leng, A. Combination Gene Therapy Using VEGF-shRNA and Fusion Suicide Gene yCDglyTK Inhibits Gastric Carcinoma Growth Exp. Mol. Pathol. 2011, 91, 745-752
7. Xue, Y.; Religa, P.; Cao, R.; Hansen, A. J.; Lucchini, F.; Jones, B.; Wu, Y.; Zhu, Z.; Pytowski, B.; Liang, Y. et al. Anti-VEGF Agents Confer Survival Advantages to Tumor-Bearing Mice by Improving Cancer-Associated Systemic Syndrome Proc. Natl. Acad. Sci. U.S.A. 2008, 105, 18513-18518
8. Reardon, D. A.; Wen, P. Y.; Desjardins, A.; Batchelor, T. T.; Vredenburgh, J. J. Glioblastoma Multiforme: An Emerging Paradigm of Anti-VEGF Therapy Expert Opin. Biol. Ther. 2008, 8, 541-553
9. Miletic, H.; Niclou, S. P.; Johansson, M.; Bjerkvig, R. Anti-VEGF Therapies for Malignant Glioma: Treatment Effects and Escape Mechanisms Expert Opin. Ther. Targets 2009, 13, 455-468
10. Wick, W.; Weller, M.; van den Bent, M.; Stupp, R. Bevacizumab and Recurrent Malignant Gliomas: A European Perspective J. Clin. Oncol. 2010, 28, 188-189
11. Aagaard, L.; Rossi, J. J. RNAi Therapeutics: Principles, Prospects and Challenges Adv. Drug Delivery Rev. 2007, 59, 75-86
12. Hu, Q.; Li, W.; Hu, X.; Hu, Q.; Shen, J.; Jin, X.; Zhou, J.; Tang, G.; Chu, P. K. Synergistic Treatment of Ovarian Cancer by Co-delivery of Survivin shRNA and Paclitaxel via Supramolecular Micellar Assembly Biomaterials 2012, 33, 6580-6591
13. Guan, H.; Zhou, Z.; Wang, H.; Jia, S. F.; Liu, W.; Kleinerman, E. S. A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Inhibits Ewing's Sarcoma Growth in a Xenograft Mouse Model Clin. Cancer Res. 2005, 11, 2662-2669
14. Detwiller, K. Y.; Fernando, N. T.; Segal, N. H.; Ryeom, S. W.; D'Amore, P. A.; Yoon, S. S. Analysis of Hypoxia-Related Gene Expression in Sarcomas and Effect of Hypoxia on RNA Interference of Vascular Endothelial Cell Growth Factor A Cancer Res. 2005, 65, 5881-5889
15. Salva, E.; Kabasakal, L.; Eren, F.; Cakalagaoglu, F.; Ozkan, N.; Akbuga, J. Chitosan/Short Hairpin RNA Complexes for Vascular Endothelial Growth Factor Suppression Invasive Breast Carcinoma Oligonucleotides 2010, 20, 183-190
16. Ren, B.; Song, K.; Parangi, S.; Jin, T.; Ye, M.; Humphreys, R.; Duquette, M.; Zhang, X.; Benhaga, N.; Lawler, J. et al. A Double Hit To Kill Tumor and Endothelial Cells by TRAIL and Antiangiogenic 3TSR Cancer Res. 2009, 69, 3856-3865
17. Zhu, C.; Jung, S.; Luo, S.; Meng, F.; Zhu, X.; Park, T. G.; Zhong, Z. Co-delivery of siRNA and Paclitaxel into Cancer Cells by Biodegradable Cationic Micelles Based on PDMAEMA-PCL-PDMAEMA Triblock Copolymers Biomaterials 2010, 31, 2408-2416
18. Bagalkot, V.; Lee, I. H.; Yu, M. K.; Lee, E.; Park, S.; Lee, J. H.; Jon, S. A Combined Chemoimmunotherapy Approach Using a Plasmid-Doxorubicin Complex Mol. Pharmaceutics 2009, 6, 1019-1028
19. Bagalkot, V.; Farokhzad, O. C.; Langer, R.; Jon, S. An Aptamer-Doxorubicin Physical Conjugate as a Novel Targeted Drug-Delivery Platform Angew. Chem., Int. Ed. 2006, 45, 8149-8152
20. Guo, L.; Fan, L.; Pang, Z.; Ren, J.; Ren, Y.; Li, J.; Chen, J.; Wen, Z.; Jiang, X. TRAIL and Doxorubicin Combination Enhances Anti-glioblastoma Effect Based on Passive Tumor Targeting of Liposomes J. Controlled Release 2011, 154, 93-102
21. Han, L.; Huang, R.; Li, J.; Liu, S.; Huang, S.; Jiang, C. Plasmid pORF-hTRAIL and Doxorubicin Co-delivery Targeting to Tumor Using Peptide-Conjugated Polyamidoamine Dendrimer Biomaterials 2011, 32, 1242-1252
22. Schwartz, S. M.; Heimark, R. L.; Majesky, M. W. Developmental Mechanisms Underlying Pathology of Arteries Physiol. Rev. 1990, 70, 1177-1209
23. Klagsbrun, M. Regulators of Angiogenesis: Stimulators, Inhibitors, and Extracellular Matrix J. Cell. Biochem. 1991, 47, 199-200
24. Pisters, P. W.; Patel, S. R.; Prieto, V. G.; Thall, P. F.; Lewis, V. O.; Feig, B. W.; Hunt, K. K.; Yasko, A. W.; Lin, P. P.; Jacobson, M. G. et al. Phase I Trial of Preoperative Doxorubicin-Based Concurrent Chemoradiation and Surgical Resection for Localized Extremity and Body Wall Soft Tissue Sarcomas J. Clin. Oncol. 2004, 22, 3375-3380
25. Bartlett, D. W.; Su, H.; Hildebrandt, I. J.; Weber, W. A.; Davis, M. E. Impact of Tumor-Specific Targeting on the Biodistribution and Efficacy of siRNA Nanoparticles Measured by Multimodality In Vivo Imaging Proc. Natl. Acad. Sci. U.S.A. 2007, 104, 15549-15554
26. Torchilin, V. Tumor Delivery of Macromolecular Drugs Based on the EPR Effect Adv. Drug Delivery Rev. 2011, 63, 131-135
27. Matsumura, Y.; Oda, T.; Maeda, H. General Mechanism of Intratumor Accumulation of Macromolecules: Advantage of Macromolecular Therapeutics Gan to Kagaku Ryoho 1987, 14, 821-829
28. Vives, E.; Schmidt, J.; Pelegrin, A. Cell-Penetrating and Cell-Targeting Peptides in Drug Delivery Biochim. Biophys. Acta 2008, 1786, 126-138
29. Vives, E. Present and Future of Cell-Penetrating Peptide Mediated Delivery Systems: "Is the Trojan Horse Too Wild To Go Only to Troy?" J. Controlled Release 2005, 109, 77-85
30. Heitz, F.; Morris, M. C.; Divita, G. Twenty Years of Cell-Penetrating Peptides: From Molecular Mechanisms to Therapeutics Br. J. Pharmacol. 2009, 157, 195-206
31. Aguilera, T. A.; Olson, E. S.; Timmers, M. M.; Jiang, T.; Tsien, R. Y. Systemic In Vivo Distribution of Activatable Cell Penetrating Peptides Is Superior to That of Cell Penetrating Peptides Integr. Biol. 2009, 1, 371-381
32. Jiang, T.; Olson, E. S.; Nguyen, Q. T.; Roy, M.; Jennings, P. A.; Tsien, R. Y. Tumor Imaging by Means of Proteolytic Activation of Cell-Penetrating Peptides Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17867-17872
33. Lee, E. S.; Gao, Z.; Bae, Y. H. Recent Progress in Tumor pH Targeting Nanotechnology J. Controlled Release 2008, 132, 164-170
34. Egeblad, M.; Werb, Z. New Functions for the Matrix Metalloproteinases in Cancer Progression Nat. Rev. Cancer 2002, 2, 161-174
35. Cottet, H.; Martin, M.; Papillaud, A.; Souaid, E.; Collet, H.; Commeyras, A. Determination of Dendrigraft Poly- l -lysine Diffusion Coefficients by Taylor Dispersion Analysis Biomacromolecules 2007, 8, 3235-3243
36. Huang, R.; Liu, S.; Shao, K.; Han, L.; Ke, W.; Liu, Y.; Li, J.; Huang, S.; Jiang, C. Evaluation and Mechanism Studies of PEGylated Dendrigraft Poly- l -Lysines as Novel Gene Delivery Vectors Nanotechnology 2010, 21, 265101
37. de Vries, N. A.; Beijnen, J. H.; Boogerd, W.; van Tellingen, O. Blood-Brain Barrier and Chemotherapeutic Treatment of Brain Tumors Expert Rev. Neurother. 2006, 6, 1199-1209
38. Friedman, H. S.; Prados, M. D.; Wen, P. Y.; Mikkelsen, T.; Schiff, D.; Abrey, L. E.; Yung, W. K.; Paleologos, N.; Nicholas, M. K.; Jensen, R. et al. Bevacizumab Alone and in Combination with Irinotecan in Recurrent Glioblastoma J. Clin. Oncol. 2009, 27, 4733-4740
39. Clark, M. J.; Homer, N.; O'Connor, B. D.; Chen, Z.; Eskin, A.; Lee, H.; Merriman, B.; Nelson, S. F. U87MG Decoded: The Genomic Sequence of a Cytogenetically Aberrant Human Cancer Cell Line PLoS Genet. 2010, 6, e1000832
40. Im, S. A.; Gomez-Manzano, C.; Fueyo, J.; Liu, T. J.; Ke, L. D.; Kim, J. S.; Lee, H. Y.; Steck, P. A.; Kyritsis, A. P.; Yung, W. K. Antiangiogenesis Treatment for Gliomas: Transfer of Antisense-Vascular Endothelial Growth Factor Inhibits Tumor Growth in vivo Cancer Res. 1999, 59, 895-900
41. Potocky, T. B.; Menon, A. K.; Gellman, S. H. Cytoplasmic and Nuclear Delivery of a TAT-Derived Peptide and a β-Peptide after Endocytic Uptake into HeLa Cells J. Biol. Chem. 2003, 278, 50188-50194
42. Pouton, C. W.; Seymour, L. W. Key Issues in Non-viral Gene Delivery Adv. Drug Delivery Rev. 2001, 46, 187-203
43. Jiang, T.; Olson, E. S.; Nguyen, Q. T.; Roy, M.; Jennings, P. A.; Tsien, R. Y. Tumor Imaging by Means of Proteolytic Activation of Cell-Penetrating Peptides Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17867-17872
44. Danial, N. N.; Korsmeyer, S. J. Cell Death: Critical Control Points Cell 2004, 116, 205-219
45. Jain, R. K. Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy Science 2005, 307, 58-62
46. Schutters, K.; Reutelingsperger, C. Phosphatidylserine Targeting for Diagnosis and Treatment of Human Diseases Apoptosis 2010, 15, 1072-1082
47. Ghoroghchian, P. P.; Therien, M. J.; Hammer, D. A. In Vivo Fluorescence Imaging: A Personal Perspective Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2009, 1, 156-167
48. Vredenburgh, J. J.; Desjardins, A.; Herndon, J. E., II; Dowell, J. M.; Reardon, D. A.; Quinn, J. A.; Rich, J. N.; Sathornsumetee, S.; Gururangan, S.; Wagner, M. et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma Clin. Cancer Res. 2007, 13, 1253-1259
49. Bisacchi, D.; Benelli, R.; Vanzetto, C.; Ferrari, N.; Tosetti, F.; Albini, A. Anti-angiogenesis and Angioprevention: Mechanisms, Problems and Perspectives Cancer Detect. Prev. 2003, 27, 229-238
50. Thurston, G.; McLean, J. W.; Rizen, M.; Baluk, P.; Haskell, A.; Murphy, T. J.; Hanahan, D.; McDonald, D. M. Cationic Liposomes Target Angiogenic Endothelial Cells in Tumors and Chronic Inflammation in Mice J. Clin. Invest. 1998, 101, 1401-1413